ImmunoGen Plunges After Phase III Ovarian Cancer Treatment Fails to Hit PFS Endpoint

Shares of Waltham, Mass.-based ImmunoGen, Inc. have plunged nearly 50 percent in premarket trading after the company’s Phase III ovarian cancer treatment failed to meet the primary endpoint of progression-free survival.